Clinical characteristics of liver transplant recipients with HCC by recipient sex after PSM
| Variables | Male recipient n = 764 | Female recipient n = 382 | P value | SMD |
|---|---|---|---|---|
| Donor age | 0.87 | −0.01 | ||
| < 50 y | 444 (58.12%) | 220 (57.59%) | ||
| ≥ 50 y | 320 (41.88%) | 162 (42.41%) | ||
| Donor sex | 0.80 | −0.01 | ||
| Male | 601 (78.66%) | 298 (78.01%) | ||
| Female | 163 (21.34%) | 84 (21.99%) | ||
| Donor BMI | 22.8 (20.8–24.4) | 22.9 (20.8–24.5) | 0.62 | −0.03 |
| Donor type | 0.87 | −0.01 | ||
| DBD | 432 (56.54%) | 214 (56.02%) | ||
| DCD | 332 (43.46%) | 168 (43.98%) | ||
| ABO blood incompatibility | 0.64 | −0.03 | ||
| Incompatible | 13 (1.70%) | 8 (2.09%) | ||
| Compatible | 751 (98.30%) | 374 (97.91%) | ||
| Recipient age | 0.76 | 0.02 | ||
| < 50 y | 271 (35.47%) | 139 (36.39%) | ||
| ≥ 50 y | 493 (64.53%) | 243 (63.61%) | ||
| Hypertension | 0.88 | −0.01 | ||
| No | 698 (91.36%) | 348 (91.10%) | ||
| Yes | 66 (8.64%) | 34 (8.90%) | ||
| Diabetes | 0.83 | −0.02 | ||
| No | 734 (96.07%) | 366 (95.81%) | ||
| Yes | 30 (3.93%) | 16 (4.19%) | ||
| HBsAg | 0.88 | −0.01 | ||
| Negative | 165 (21.60%) | 84 (21.99%) | ||
| Positive | 599 (78.40%) | 298 (78.01%) | ||
| Child-Pugh classification | 0.99 | 0.01 | ||
| A | 157 (20.55%) | 80(20.94%) | ||
| B | 287 (37.57%) | 143 (37.43%) | ||
| C | 320 (41.88%) | 159(41.62%) | ||
| Any TACE | 0.95 | −0.01 | ||
| No | 653 (85.47%) | 326 (85.34%) | ||
| Yes | 111 (14.53%) | 56 (14.66%) | ||
| Any RFA | 0.58 | 0.04 | ||
| No | 720 (94.24%) | 363 (95.03%) | ||
| Yes | 44 (5.76%) | 19 (4.97%) | ||
| MELD | 14 (9–29) | 14 (9–30) | 0.72 | −0.02 |
| Beyond Milan criteria | 0.69 | 0.03 | ||
| No | 495 (64.79%) | 243 (63.61%) | ||
| Yes | 269 (35.21%) | 139 (36.39%) | ||
| Beyond Hangzhou criteria | 0.62 | 0.03 | ||
| No | 670 (87.70%) | 331 (86.65%) | ||
| Yes | 94 (12.30%) | 51 (13.35%) | ||
| Largest tumor size | 0.59 | −0.05 | ||
| < 3 cm | 318(41.62%) | 147 (38.48%) | ||
| 3–5 cm | 314 (41.10%) | 166 (43.46%) | ||
| > 5 cm | 132 (17.28%) | 69 (18.06%) | ||
| Tumor number | 1.00 | 0 | ||
| Single | 496 (64.92%) | 248 (64.92%) | ||
| Multiple | 268 (35.08%) | 134 (35.08%) | ||
| Microsatellite | 1.00 | 0 | ||
| No | 706 (92.41%) | 353 (92.41%) | ||
| Yes | 58 (7.59%) | 29 (7.59%) | ||
| Cold ischemia time (h) | 6.0 (4.4–7.5) | 6.0 (4.5–7.8) | 0.43 | −0.05 |
| Operative time (h) | 6.9 (6.0–8.0) | 6.9 (5.8–8.1) | 0.91 | −0.002 |
| Operative bleeding (mL) | 800 (500–1500) | 900 (500–1500) | 0.77 | −0.02 |
| Salvage LT | 0.53 | 0.04 | ||
| No | 664 (86.91%) | 337 (88.22%) | ||
| Yes | 100 (13.09%) | 45 (11.78%) | ||
| Follow-up time (months) | 29.1 (18.0–41.6) | 30.1 (18.4–42.7) | 0.43 | −0.05 |
PSM, propensity score matching; LT, liver transplantation; BMI, body mass index; MELD, model for end-stage liver disease; CHILD, Child-Pugh; DBD, donation after brain death; DCD, donation after circulatory death; DBCD, donation after brain and cardiac death; RFA, radiofrequency ablation; TACE, transcatheter arterial chemoembolization; SMD, standardized mean difference.